Skip to content

Inspection Record

Granules Pharmaceuticals Inc. — FDA 483 Findings

US FDAInspected 2026-04-03Published 2026-10-23 4 findingsStability and storageEquipment and facilityDeviation, CAPA, and investigationDocumentation and records

Inspectors David A Oluwo · Ofuje D DaniyanThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

2Equipment and facility

Buildings used in the holding of a drug product are not maintained in a good state of repair.

3Deviation, CAPA, and investigation

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

4Documentation and records

Batch production and control records do not include complete information relating to the production and control of each batch.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-23. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Granules Pharmaceuticals Inc. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.